Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.

Abstract

BACKGROUND:

Obtaining tumor samples for epidermal growth factor receptor (EGFR) mutation analysis during treatment can be difficult; therefore, serum samples may be a convenient alternative. We analyzed serum EGFR mutations in the Japanese phase 2 JO22903 study in chemotherapy-naive non-small-cell lung cancer patients with tumor EGFR mutations.

MATERIALS AND METHODS:

Serum samples were analyzed by Scorpion-ARMS to detect EGFR mutations before and after erlotinib administration. Agreement between serum and tumor EGFR mutations and time course changes of EGFR mutations were evaluated.

RESULTS:

A total of 95 of 103 patients consented to examination of serum samples; baseline serum EGFR mutations (exon 19 deletions or L858R) were detected in 25 patients (26.3%). The agreement rate between tumor and serum samples was 96.2%. Among 65 serum samples taken at 190 days after treatment initiation, EGFR mutations were detected in 5 patients (7.7%). Of the serum samples taken at progression (n = 71), EGFR mutations were detected in 16 patients (22.5%). Patients with baseline serum EGFR mutations had a median progression-free survival of 9.7 months; those without baseline serum mutations had a median progression-free survival of 15.2 months.

CONCLUSION:

The sensitivity of these analyses was not enough to draw firm conclusions; however, the results suggest that serum EGFR mutations correlate with disease activity.

• Authors: Makoto Nishio, Koichi Goto, Kenichi Chikamori, Toyoaki Hida, Nobuyuki Katakami, Makoto Maemondo, Norihisa Ohishi, Tomohide Tamura
• Journal: Clinical lung cancer (Clin Lung Cancer) Vol. 17 Issue 1 Pg. 24-9.e1 (Jan 2016) ISSN: 1938-0690 [Electronic] United States
• PMID: 26336854 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• Biomarkers, Tumor
• Protein Kinase Inhibitors
• Erlotinib Hydrochloride
• EGFR protein, human
• ErbB Receptors

Topics

• Adult
• Aged
• Aged, 80 and over
• Biomarkers, Tumor (blood, genetics)
• Carcinoma, Non-Small-Cell Lung (blood, drug therapy, genetics, pathology)
• Disease Progression
• ErbB Receptors (blood, genetics)
• Erlotinib Hydrochloride (therapeutic use)
• Female
• Follow-Up Studies
• Genotype
• Humans
• Lung Neoplasms (blood, drug therapy, genetics, pathology)
• Male
• Middle Aged
• Mutation (genetics)
• Neoplasm Staging
• Polymerase Chain Reaction
• Prognosis
• Protein Kinase Inhibitors (therapeutic use)
• Survival Rate